Compare ARDX & WGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | WGO |
|---|---|---|
| Founded | 2007 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.0B |
| IPO Year | 2014 | 1994 |
| Metric | ARDX | WGO |
|---|---|---|
| Price | $5.71 | $33.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 12 |
| Target Price | $15.14 | ★ $43.36 |
| AVG Volume (30 Days) | ★ 3.7M | 443.8K |
| Earning Date | 05-12-2026 | 03-30-2026 |
| Dividend Yield | N/A | ★ 4.08% |
| EPS Growth | N/A | ★ 106.82 |
| EPS | N/A | ★ 0.19 |
| Revenue | $2,607,000.00 | ★ $1,985,674,000.00 |
| Revenue This Year | $38.22 | $5.46 |
| Revenue Next Year | $33.85 | $4.88 |
| P/E Ratio | ★ N/A | $180.79 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.50 | $28.29 |
| 52 Week High | $8.40 | $50.16 |
| Indicator | ARDX | WGO |
|---|---|---|
| Relative Strength Index (RSI) | 35.22 | 16.12 |
| Support Level | $5.49 | $32.59 |
| Resistance Level | $6.23 | $34.25 |
| Average True Range (ATR) | 0.31 | 1.68 |
| MACD | -0.06 | -0.88 |
| Stochastic Oscillator | 13.41 | 1.71 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Winnebago Industries manufactures Class A, B, and C motor homes along with towables, customized specialty vehicles, boats, and parts. Headquartered in Eden Prairie, Minnesota, Winnebago has been producing recreational vehicles since 1958. Revenue was $2.8 billion in fiscal 2025. Winnebago expanded into towables in 2011 with the acquisition of SunnyBrook and acquired Grand Design in November 2016. Towables made up 84% of the firm's RV unit volume, up from 31% in fiscal 2016. The company's total fiscal 2025 RV unit volume was 36,911. Winnebago expanded into boating in 2018 with the purchase of Chris-Craft, bought premium motor home maker Newmar in November 2019, and bought Barletta pontoon boats in August 2021. It also is developing electric and autonomous technology.